The Patent Finder

Inhibitors of Human Tumor-Expressed CCXCKR2

Chemocentryx, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 60/949,328, filed Jul 12, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 7,649,011Inhibitors of Human Tumor-Expressed CCXCKR2
In force
 · High confidence
ChemocentryxIn force
High confidence
US 7,572,600Enzymatic Activities in Chemokine-Mediated Inflammation
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
US 7,683,176Triazolyl Pyridyl Benzenesulfonamides
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
US 7,718,683Triazolyl Phenyl Benzenesulfonamides
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
US 9,409,909N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES and N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES
In force
 · Medium confidence
ChemoCentryx, Inc.In force
Medium confidence
US 8,546,408Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
US 9,394,307Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
US 9,745,312Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation
In force
 · High confidence
ChemoCentryx, Inc.In force
High confidence
US 10,208,050Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
US 10,899,765Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation
In force
 · High confidence
Chemocentryx, Inc.In force
High confidence
33 more patents in this group · Pro
10 of 43 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 43, including 14 expired and 4 expiring within the 18 months from Nov 16, 2026.
Upgrade to Pro
16 of these are in force and held by Chemocentryx, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited